Cipla Poses Strong Competition For GSK And Gilead

GlaxoSmithKline's (GSK) blockbuster drug Advair is expected to face stiff competition from an Indian generic-drug maker Cipla Ltd (CIPLA), which plans to launch a generic version of the anti-asthma drug by the end of 2014.